We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Issues Guidance on Trials for Treatment of Symptom-Free Cirrhosis
FDA Issues Guidance on Trials for Treatment of Symptom-Free Cirrhosis
Drug sponsors should “be careful” to make sure they’re properly screening treatments for nonalcoholic steatohepatitis (NASH) compensated cirrhosis patients for Phase 3 clinical trials , the FDA says in a new draft guidance issued Friday.